Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.54 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021376 | 0.83 | ALDH1A3 (0.49) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL14329287 | 0.83 | ALDH1A3 (0.49) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL17157479 | 0.83 | ALDH1A3 (0.53) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL22490053 | 0.82 | ALDH1A3 (0.47) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL16955992 | 0.82 | ALDH1A3 (0.40) | ALDH1A3ALDH1A1ALDH3A1MAPTSMN1; SMN2 | |
| SCHEMBL16957022 | 0.82 | ALDH1A3 (0.40) | ALDH1A3ALDH1A1ALDH3A1MAPTTSHR | |
| SCHEMBL2735985 | 0.82 | ALDH1A3 (0.47) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL29214423 | 0.81 | ALDH1A3 (0.47) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL606640 | 0.80 | ALDH1A1 (0.45) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT | |
| SCHEMBL28829387 | 0.80 | ALDH1A3 (0.46) | ALDH1A3ALDH1A1ALDH3A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057059-B | Deuterated compounds useful as KRAS G12D inhibitors | 南京燧坤智能科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116057059-A | Deuterated compounds useful as KRAS G12D inhibitors | 南京燧坤智能科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2022262838-A1 | DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022262838-A1 | DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| EP-2199290-B1 | Method of nucleating a polyolefin composition with acetal-based compounds | MILLIKEN & CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1740653-B1 | METHOD OF NUCLEATING A POLYOLEFIN COMPOSITION WITH ACETAL-BASED COMPOUNDS | MILLIKEN & CO (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2199290-A2 | Method of nucleating a polyolefin composition with acetal-based compounds | Milliken & Company (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20030127631-A1 | Novel symmetrical halogenated and alkylated alditol derivatives and compositions and articles containing same | ANDERSON JOHN D (US) | 2003-07-10 | — | — | US | disclosed |
| US-6547988-B2 | Plastic additives which are useful as nucleating agents and which are especially useful for improving the optical properties of polymeric materials; also useful as gelling agents for water and organic solvents | MILLIKEN & COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030008951-A1 | Novel symmetrical halogenated and alkylated alditol derivatives and compositions and articles containing same | MILLIKEN & COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-6500964-B2 | BY REACTING SUBSTITUTED BENZALDEHYDE(S) WITH ALDITOL(S) SUCH AS SORBITOL | MILLIKEN & COMPANY | 2002-12-31 | — | — | US | disclosed |
| WO-2002079124-A2 | METHOD OF PRODUCING HIGH YIELD ALDITOL ACETALS WITH MINERAL ACIDS AND SURFACTANTS | MILLIKEN & COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002077086-A2 | NOVEL SYMMETRICAL SUBSTITUTED BENZALDEHYDE ALDITOL DERIVATIVES AND COMPOSITIONS AND ARTICLES CONTAINING SAME | MILLIKEN & COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020137953-A1 | Method of producing high yield alditol acetals with mineral acids and surfactants | MILLIKEN & COMPANY | 2002-09-26 | — | — | US | disclosed |
| EP-0254578-B1 | ANTIBIOTIC INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| US-4772694-A | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0254578-A1 | Antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008951-A1 | Novel symmetrical halogenated and alkylated alditol derivatives and compositions and articles containing same | ADH1C, ADH1A, ALDOA | ALDH1A3 55/4885ALDH1A1 69/4885ALDH3A1 9/4885 |
| US-20020137953-A1 | Method of producing high yield alditol acetals with mineral acids and surfactants | SORD, ALDOA, DERA | ALDH1A3 1159/4885ALDH1A1 1328/4885ALDH3A1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.